Skip to content
DataLookout
Menu

NCT07752407

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 0 → 26 locations
  2. Notable Recruitment opened
    • Eligibility criteria expanded, about 39 words
    • Study sites: 0 to 1
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Treated Heartburn Episodes Achieving Complete Relief at 2 Hours and Sustained Relief for 24 Hours up to Week 12
Timeframe: Up to Week 12

Secondary (7)

Percentage of Treated Heartburn Episodes Improved at 2 Hours With Sustained Relief for 24 Hours up to Week 12
Percentage of Treated Heartburn Episodes Improved at 1 Hour With Sustained Relief for 24 Hours up to Week 12
Percentage of Treated Heartburn Episodes Improved at 2 Hours up to Week 12
Percentage of Treated Heartburn Episodes Improved at 1 Hour up to Week 12
Percentage of Treated Heartburn Episodes Achieving Complete Relief at 2 Hours and Sustained Relief for 24 hours up to Week 24
Show 2 moreShow less
Percentage of Treated Heartburn Episodes Improved at 30 Minutes With Sustained Relief for 24 Hours up to Week 12
Percentage of Treated Heartburn Episodes Improved at 30 Minutes up to Week 12

Arms and interventions

Vonoprazan 10 mgExperimental

Participants will be administered open-label vonoprazan 10 mg once daily (QD) to be taken orally for 4 weeks during the 4-week run-in period. Participants will be administered vonoprazan 10 mg to be taken orally as needed at the onset of each heartburn episode (maximum of once in a 24-hour period) during the 12-week placebo-controlled timed assessment period and the subsequent 12-week placebo-controlled extension period.

PlaceboPlacebo comparator

Participants will be administered open-label vonoprazan 10 mg QD to be taken orally for 4 weeks during the 4-week run-in period. Participants will be administered placebo to be taken orally as needed at the onset of each heartburn episode (maximum of once in a 24-hour period) during the 12-week placebo-controlled timed assessment period and the subsequent 12-week placebo-controlled extension period.

Drugs: Vonoprazan, Placebo

Sites

26 sites in 1 country